세계의 당뇨병성 족궤양 치료 시장 : 제품별, 최종 사용자별 - 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Diabetic Foot Ulcer Treatment Market," The diabetic foot ulcer treatment market was valued at $4.4 billion in 2022, and is estimated to reach $7.4 billion by 2032, growing at a CAGR of 5.4% from 2023 to 2032. Diabetic foot ulcers are a common and serious complication of diabetes mellitus. They are open sores or wounds that typically develop on the feet of individuals with diabetes. Diabetic foot ulcers are a result of various factors, including poor circulation, nerve damage (neuropathy), and impaired immune function, which are all associated with diabetes. If left untreated, diabetic foot ulcer can become chronic, leading to severe complications such as infection, gangrene, and even amputation. Thus, proper management and treatment of diabetic foot ulcers are crucial to prevent these complications and promote wound healing.

The major factors driving the development of the diabetic foot ulcer treatments are increasing number of individuals suffering from diabetic foot ulcers, rise in R & D exercises, and surge in awareness about proper diabetic foot care. The predominance of diabetes is on the rise across the globe, fueled through factors which include sedentary life, unhealthy diets, and growing obesity. Further, delayed periods of high blood sugar level can result in peripheral neuropathy, a condition that harms the nerves in the toes and diminishes sensation. In addition, poor blood circulation, known as peripheral arterial disease, advance impairs wound healing within the feet. These components, combined with the developing diabetic populace, contribute to an expanded frequency of diabetic foot ulcers. For instance, as per, Centers for Disease Control and Prevention (CDC), 2022, almost 12% individuals with diabetes develop diabetic foot ulcers in U.S. Thus, increasing number of individuals suffering from diabetic foot ulcer has driven the request for compelling treatment options and thereby, propelling the development of the diabetic foot ulcer treatment market.

In addition, researchers and medical experts are actively involved in studying the pathophysiology of diabetic foot ulcers, exploring new treatment modalities and improving existing healing procedures. The use of advanced technology has caused the improvement of modern wound care products, bioengineered pores and skin substitutes and off-loading devices. These improvements aim to enhance wound healing, protect infections, and offer better management options for diabetic foot ulcers. Further, there are ongoing studies in field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing. The growing funding in research and development activities by pharmaceutical organizations, instructional institutions and healthcare companies has expanded the invention of novel therapeutic strategies, fueling the growth of the market.

Furthermore, surge in awareness about proper diabetic foot care has contributed to the growth of the diabetic foot ulcer treatment market. Healthcare organizations, diabetes associations, and healthcare professionals had been actively raising focus about the importance of foot care in individuals with diabetes. Diabetic foot ulcers can be averted or minimized through regular foot examinations, right shoes, foot hygiene, and early detection of foot ulcers. Furthermore, education campaigns and initiatives aimed at improving foot care practices have led to increased patient awareness and engagement. As individuals become more aware about the risks and consequences of diabetic foot ulcers, they are more anticipated to seek timely medical attention and adhere to preventive measures. This heightened awareness has not only improved patient outcomes but has also driven the demand for diabetic foot ulcer treatment options.

The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global diabetic foot ulcer treatment market are ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch, and product approval to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic foot ulcer treatment market analysis from 2022 to 2032 to identify the prevailing diabetic foot ulcer treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the diabetic foot ulcer treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global diabetic foot ulcer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

• Wound care dressings
• Wound care devices
  • Type
  • Negative pressure wound therapy
  • Others
• Biologics
• Others

By Type

• Neuropathic ulcers
• Ischemic ulcers
• Neuroischemic ulcers

By End user

• Hospitals
• Homecare settings
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• 3M Company
• B. Braun SE
• Cardinal Health Inc.
• Coloplast
• ConvaTec Group plc
• Essity Aktiebolag AB
• Integra LifeSciences Holdings Corporation
• Molnlycke Health Care AB
• ORGANOGENESIS HOLDINGS INC.
• Smith and Nephew plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. High bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. High bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of diabetic foot ulcer
    • 3.4.1.2. Technological advancements in wound care management
    • 3.4.1.3. Rise in new product launches for diabetic foot ulcer treatment

• 3.4.2. Restraints
  • 3.4.2.1. Stringent regulations for manufacturing of wound care products

• 3.4.3. Opportunities
  • 3.4.3.1. Growing opportunity in emerging markets

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Wound care dressings
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Wound care devices
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Wound care devices Diabetic Foot Ulcer Treatment Market by Type
• 4.4. Biologics
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Neuropathic ulcers
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Ischemic ulcers
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Neuroischemic ulcers
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Homecare settings
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Product
  • 7.2.3. Market size and forecast, by Type
  • 7.2.4. Market size and forecast, by End user
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Product
    • 7.2.5.1.3. Market size and forecast, by Type
    • 7.2.5.1.4. Market size and forecast, by End user
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Product
    • 7.2.5.2.3. Market size and forecast, by Type
    • 7.2.5.2.4. Market size and forecast, by End user
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Product
    • 7.2.5.3.3. Market size and forecast, by Type
    • 7.2.5.3.4. Market size and forecast, by End user
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Product
  • 7.3.3. Market size and forecast, by Type
  • 7.3.4. Market size and forecast, by End user
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Product
    • 7.3.5.1.3. Market size and forecast, by Type
    • 7.3.5.1.4. Market size and forecast, by End user
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Product
    • 7.3.5.2.3. Market size and forecast, by Type
    • 7.3.5.2.4. Market size and forecast, by End user
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Product
    • 7.3.5.3.3. Market size and forecast, by Type
    • 7.3.5.3.4. Market size and forecast, by End user
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Product
    • 7.3.5.4.3. Market size and forecast, by Type
    • 7.3.5.4.4. Market size and forecast, by End user
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Product
    • 7.3.5.5.3. Market size and forecast, by Type
    • 7.3.5.5.4. Market size and forecast, by End user
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Product
    • 7.3.5.6.3. Market size and forecast, by Type
    • 7.3.5.6.4. Market size and forecast, by End user
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Product
  • 7.4.3. Market size and forecast, by Type
  • 7.4.4. Market size and forecast, by End user
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Product
    • 7.4.5.1.3. Market size and forecast, by Type
    • 7.4.5.1.4. Market size and forecast, by End user
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Product
    • 7.4.5.2.3. Market size and forecast, by Type
    • 7.4.5.2.4. Market size and forecast, by End user
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Product
    • 7.4.5.3.3. Market size and forecast, by Type
    • 7.4.5.3.4. Market size and forecast, by End user
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Product
    • 7.4.5.4.3. Market size and forecast, by Type
    • 7.4.5.4.4. Market size and forecast, by End user
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Product
    • 7.4.5.5.3. Market size and forecast, by Type
    • 7.4.5.5.4. Market size and forecast, by End user
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Product
    • 7.4.5.6.3. Market size and forecast, by Type
    • 7.4.5.6.4. Market size and forecast, by End user
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Product
  • 7.5.3. Market size and forecast, by Type
  • 7.5.4. Market size and forecast, by End user
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Product
    • 7.5.5.1.3. Market size and forecast, by Type
    • 7.5.5.1.4. Market size and forecast, by End user
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Product
    • 7.5.5.2.3. Market size and forecast, by Type
    • 7.5.5.2.4. Market size and forecast, by End user
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Product
    • 7.5.5.3.3. Market size and forecast, by Type
    • 7.5.5.3.4. Market size and forecast, by End user
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Product
    • 7.5.5.4.3. Market size and forecast, by Type
    • 7.5.5.4.4. Market size and forecast, by End user

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. ConvaTec Group plc
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. 3M Company
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Cardinal Health Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. ORGANOGENESIS HOLDINGS INC.
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Smith and Nephew plc.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. B. Braun SE
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Coloplast
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Integra LifeSciences Holdings Corporation
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Molnlycke Health Care AB
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Essity Aktiebolag AB
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments